Ripretinib Safer Than Sunitinib for GIST, Fails to Improve P

The findings suggest that ripretinib (Qinlock) provides a similar PFS benefit but may come with notably better tolerability compared with sunitinib.

Related Keywords

Boston , Massachusetts , United States , Oregon , Dana Farber Cancer Institute , American , Michaelc Heinrich , , American Society Of Clinical Oncology Plenary Series , Theseus Pharmaceuticals , Oregon Health Science University , Harvard Medical School , Deciphera Pharmaceuticals , Sarcoma Center At Dana Farber Cancer Institute , Novartis , Oregon Health , Science University , American Society , Clinical Oncology Plenary , Sarcoma Center , Harvard Medical , Blueprint Medicines , Gist , Gastrointestinal Stromal Tumor , Umor Gastrointestinal Stromal , Biologic Therapy , Tyrosine Kinase Inhibitor , Rlotinib , Efitinib , Matinib , U11248 , Unitinib , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Ituximab , Rastuzumab , Neoplasm , Toxicology , Tumor , Tolerance , Sarcoma , Malignant Soft Tissue Tumor , Alopecia , Diarrhea , Fatigue , Us Fo ,